Adam Hacker, PhD Joins Autolus as Senior Vice President for Regulatory Affairs and Quality

Company Further Strengthens Executive Team to Support Promising Clinical Pipeline LONDON, Oct. 17, 2018 -- (Healthcare Sales & Marketing Network) -- Autolus Therapeutics plc (NASDAQ: AUTL), a clinical-stage biopharmaceutical company developing next-gen... Biopharmaceuticals, Oncology, Personnel Autolus Therapeutics, T-cell therapies
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news